ClinicalTrials.Veeva

Menu

Phentolamine Mesylate vs. Diode Laser for Anaesthesia Reversal (RCT)

S

sara nabil

Status and phase

Completed
Phase 3

Conditions

Reversal of Local Anesthesia in Children

Treatments

Device: diode laser
Drug: OraVerse Injectable Product

Study type

Interventional

Funder types

Other

Identifiers

NCT05473858
AlAzhar

Details and patient eligibility

About

"Randomised three-arm trial comparing phentolamine mesylate (OraVerse), 650-nm diode laser and no intervention for accelerating reversal of soft-tissue anaesthesia after 4% articaine (1:100,000 epinephrine) buccal infiltration in children aged 8-10 years.

Full description

Conducted design: 36 children aged 8-10 years requiring extraction of a mandibular first primary molar received 1.4 mL of 4% articaine with 1:100,000 epinephrine by buccal infiltration and were randomised 1:1:1 to three parallel groups (n = 12 each). Twenty minutes after injection: (1) Control - no intervention; (2) OraVerse - phentolamine mesylate 1.4 mL at the same site and technique; (3) Laser - 650-nm diode laser at seven points (4 intraoral, 3 extraoral), 25 s per point, total energy 12.5 J. The outcome assessor was blinded to group allocation; participants and operators could not be blinded. Lip numbness was assessed until full recovery.

Enrollment

36 patients

Sex

All

Ages

8 to 10 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  1. Patients who need to be treated under anesthesia by injecting mandibular first molar infiltration.
  2. Cooperative children aged 8 to 10 years old with the ability to understand and respond to the sensation of soft tissue -

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

36 participants in 3 patient groups

laser group
Experimental group
Description:
"650-nm diode laser (LX16Plus, Woodpecker), 7 points (4 intraoral, 3 extraoral), 25 s per point, 50 mW intraoral / 100 mW extraoral, total energy 12.5 J, applied 20 minutes after injection." 12 Arms → OraVerse group "injection of oraverse," No dose or timing.
Treatment:
Device: diode laser
oraverse group
Experimental group
Description:
"Phentolamine mesylate (OraVerse) 1.4 mL injected at the anaesthetic injection site, same technique, 20 minutes after injection
Treatment:
Drug: OraVerse Injectable Product
Control group
No Intervention group
Description:
Articane infiltration only; no reversal intervention." 11 Arms → Laser group "patient exposed to diode laser" No laser parameters or timing. Arm type: Experimental. In

Trial contacts and locations

1

Loading...

Central trial contact

sara nabil, DR

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems